Federal Regulators Target Marketplace Brokers in Multi-Billion Dollar Healthcare Fraud Sweep

Federal health officials have issued enforcement notices to 100 insurance brokers operating within the Affordable Care Act marketplace, signaling a heightened crackdown on phantom enrollments and illegitimate subsidy payouts across public healthcare programs.

The action, announced by the Centers for Medicare & Medicaid Services under Administrator Dr. Mehmet Oz, targets agents accused of repeatedly submitting exchange applications without Social Security numbers or required identification details. According to agency estimates, approximately 35 percent of enrollments facilitated by marketplace agents could be fraudulent, potentially placing between 5 million and 6 million individuals in improperly subsidized coverage plans.

Marketplace brokers assist consumers in navigating insurance options under the Affordable Care Act. However, improper enrollment practices have posed persistent challenges for federal regulators overseeing tax-credit disbursements. A Health and Human Services Department audit uncovered 2.6 million improper or unverified enrollments actively remaining in the system, more than one million of which lacked valid Social Security numbers. CMS noted that proposed regulatory reforms designed to curb these improper payouts could save taxpayers an estimated $3 billion, though agency officials attributed delayed implementation to opposition from congressional Democrats.

The enforcement actions against marketplace brokers represent one front in a broader federal campaign targeting systematic healthcare fraud. An interagency task force led by Vice President JD Vance has increasingly focused on systemic vulnerabilities across both ACA exchanges and Medicare reimbursement channels.

Earlier this year, CMS initiated regulatory inquiries into potential durable medical equipment fraud across five states—California, Florida, Maine, Minnesota, and New York. That action followed a nationwide moratorium imposed in February on newly registering suppliers of durable medical equipment, prosthetics, orthotics, and supplies.

Federal investigators have highlighted severe anomalies in specialized Medicare billing sectors, particularly regarding skin substitute products known as allografts. Medicare reimbursements for skin substitutes surged 7,100 percent in six years, rising from $200 million in 2019 to $14.4 billion in 2025.

In response to the surge, federal oversight bodies began denying 96 percent of skin substitute claims filed since March. Through May, CMS identified 4,200 suspicious allograft claims amounting to $224 million in disputed charges.